All Posts

Flexible NP opportunities across North Island (0.2 – 0.8FTE) We’re seeking NPs for contract roles across the North Island to provide weekly rounds to Aged Residential Care (ARC) facilities, delivering high-quality care to older patients with complex needs. We currently have opportunities across Northland, Waikato, Bay of Plenty, Taranaki, Manawatu, Hawkes Bay, Wairarapa and Greater Wellington. You will work closely with onsite nurses and care teams to: Provide excellent

Enhance your Dermatology Expertise: Join Our Online Session this Saturday, 16 May. Join leading New Zealand dermatology specialists in this 4-hour webinar designed to help you navigate complex cases with confidence. All registrants will enjoy continued access to the full video recording, so you won’t miss a moment - even if you can’t attend live on Saturday. Enhance your Dermatology Expertise: Join Our Online Session this Saturday, 16 May.Join leading New Zealand dermatolo

Our latest selection of CPD options for you: High-risk cutaneous squamous cell carcinoma (cSCC) WEBINAR 12 May: Rajan Patel discusses the importance of early detection and timely management of high-risk cSCC. Register here Lipids, BP, and the metabolic syndrome puzzle WEBINAR 26 May: Consultant Cardiologist Gerry Wilkins on taming the trio: Lipids, BP, and the Metabolic Syndrome. Register here Management of Diabetes and CHF WEBINAR 2 June: Ryan Paul overviews a practical

This link will take you to the proposal to enter into an agreement with Smith & Nephew for medical devices in the following categories: Surgical Implants Medical and Surgical Instruments and Power Tools Smith & Nephew’s range of medical devices are proposed to be listed on the Pharmaceutical Schedule under a Pharmac agreement from 1 July 2026. A list of products included in the proposal is attached. Pharmac welcomes feedback on this proposal. To provide feedback, please su

Accurately diagnosing and treating impetigo and intertrigo in infants is important because their skin barrier is immature, infections spread faster, and complications can escalate before anyone realises what’s happening. In her talk at the Practical Update day, Specialist Dermatologist Lisa Connelly will focus on the diagnosis and management of impetigo and intertrigo (cradle cap) in children while also distinguishing these conditions from atopic eczema. She will also discuss

Conflict in the Middle East Suppliers are working closely with Pharmac to reduce any disruption to people in New Zealand. Where issues arise, we will communicate them on our website and through this email. Conflict in the Middle East: Impact on the supply chain New medicine supply notices Hydralazine hydrochloride (20 mg ampoule) there is a supply issue affecting the Apresoline brand (Pharmacode: 274550 and 2446227). We have listed two alternatives - they have important dif

Supply issue: We are writing to inform you of a supply issue: Viatris notified Pharmac that due to delays at the manufacturing facility, Montelukast tab 5mg is in short supply. Key Date: A new brand Montelukast tab 5mg (Relonchem) is available, and has been listed (funded) from 1 May 2026. Key messages: These tablets are for paediatric use, both brands are chewable, cherry flavour. Montelukast tab 5mg (Relonchem) is a pink coloured, circular, tablet. Montelukast tab 5mg (Vi

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 1 May 2026. It includes information on: New updates Resolved Supply Issues Supply issue: Montelukast tab 5mg (Viatris) Viatris notified Pharmac that due to a delay with manufacturing Montelukast tab 5mg is in short supply.A new brand Montelukast tab 5mg (Relonchem) will be listed (funded) and available 1 May 2026 These tablets are for paediatric us

There is currently a supply issue affecting olanzapine orodispersible 10 mg and 5 mg tablets (Zypine ODT). This is due to an unexpected issue at the manufacturing site. To ensure people can continue their treatment without interruption, alternative products are being funded from 1 May 2026. All alternative products are not approved by Medsafe and therefore subject to Section 29A of the Medicines Act. Key information: Registered Product 5mg Olanzapine orodispersibl

Issue 341 - 30 April 2026 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here. You can also access other recent issues of the digest here. If you have any queries, please email us at library@health.govt.nz. Article Access For articles that aren't op

We are writing to advise you of a supply disruption affecting all strengths of Ramipril (Tryzan) due to an issue at the manufacturing site. Stock of the registered capsules is expected to run out progressively from late April through June, and no resupply of the registered product is expected until mid–late 2026. To maintain continuity of treatment, the supplier has sourced alternatives for all strengths. The alternatives products are tablets rather than capsules, and are n

Please follow this link to our website for the April 2026 Tender Notification. Ngā mihi, Jade Matthews-Wanden | Tender Analyst Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington | P: 0800 660 050 | www.pharmac.govt.nz

Early identification of AAS in younger Māori This study examined ethnic disparities in acute aortic syndrome (AAS) in Midland region patients1. Researchers conducted a 10-year retrospective review (2010–2020) of 250 consecutive AAS cases, in which Māori made up 23.3% of the population. Outcomes were compared between Māori and non-Māori. Māori patients accounted for 36.8% of cases and had a significantly higher age-standardised incidence of AAS (6.9 vs 2.0 per 100,000 person

We are writing to inform you of the: Discontinuation: Duolin nebuliser soln, salbutamol 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule New listing: Combiprasal nebuliser soln, salbutamol 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule Duolin nebuliser soln has been discontinued. The alternate Cipla brand has an expiry date of 30 June 2026. A second alternate, Combiprasal brand will be funded from 1 May 2026. Combiprasal active ingredients and

Due to a delay at the manufacturing site, there is a supply issue affecting Ezetimibe with Simvastatin 10/40 mg (Zimybe). From 1 May 2026 Pharmac is funding an alternative product Ezetimibe with Simvastatin 10/40 mg (Vytorin). This is not a Medsafe approved product and should be prescribed and supplied in line with Section 29A of the Medicines Act 1981. Further information will be added to our webpage as updates become available – Ezetimibe with simvastatin (Zimybe) 10/40 m

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 24 April 2026. It includes information on: New updates Resolved Supply Issues Discontinuation: Duolin nebuliser soln, containing salbutamol 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule New listing: Combiprasal nebuliser soln, containing salbutamol 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule Duolin nebuliser so

We’re emailing you today to let you know of a supply issue affecting the 75 mcg strength of Estradot patches. The 25 mcg, 50 mcg, 100 mcg strengths are not currently affected. We expect a shipment of more than 2 months’ supply of Estradot patches to arrive in late April, which we expect will solve the immediate issue. However, supply of Estradot could be disrupted again. This global supply issue has been ongoing since 2022 and is not related to the conflict in the Middle East

It's important to distinguish rosacea from the malar rash of lupus. Rosacea treatments are effective but should be started early, as late-stage rosacea (telangiectasias and rhinophyma) is expensive to treat cosmetically. Additionally, confusing the two risks undertreating lupus or overtreating rosacea. In his session at our Dermatology Update on Saturday May 16, Consultant Dermatologist Aaron Secrest offers a practical, pattern-based approach to determing which rash you are